We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Priority Paper EvaluationFree Access

Critical role of PTEN for development and progression of nerve sheath tumors in neurofibromatosis type 1

    Christian Mawrin

    Department of Neuropathology, University of Magdeburg, Leipziger Strasse 44, D-39120 Magdeburg, Germany.

    Search for more papers by this author

    Email the corresponding author at christian.mawrin@med.ovgu.de

    Published Online:7 Apr 2010https://doi.org/10.2217/fon.10.29

    Abstract

    Evaluation of: Gregorian C, Nakashima J, Dry SM et al.: PTEN dosage is essential for neurofibroma development and malignant transformation. Proc. Natl Acad. Sci. USA 106(46), 19479–19484 (2009). Neurofibromatosis type 1 (NF1) is among the most common inherited tumor-predisposing syndromes in humans. Development of malignant peripheral nerve sheath tumors (MPNSTs) from neurofibroma significantly affects the morbidity and mortality of NF1 patients. The authors demonstrate, using different genetically engineered mouse models, that loss of the tumor suppressor Pten in combination with overexpression of the K-ras oncogene is an important step in MPNST development. In both mouse and human tumors, the transition from low-grade neurofibromas to MPNST is associated with reduced Pten expression, deregulated mTOR signaling activity and increased proliferation. This tumor transition can be monitored by 18F-fluoro-D-glucose-PET, offering close clinical monitoring of NF1 patients and thus early detection of MPNST development in the future.

    Bibliography

    • 1  Gregorian C, Nakashima J, Dry SM et al.: PTEN dosage is essential for neurofibroma development and malignant transformation. Proc. Natl Acad. Sci. USA106(46),19479–19484 (2009).
      Medline CASGoogle Scholar
    • 2  Kourea HP, Cordon-Cardo C, Dudas M, Leung D, Woodruff JM: Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am. J. Pathol.155(6),1885–1891 (1999).
      Medline CASGoogle Scholar
    • 3  Menon AG, Anderson KM, Riccardi VM et al.: Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl Acad. Sci. USA87(14),5435–5439 (1990).
      Medline CASGoogle Scholar
    • 4  Mawrin C, Kirches E, Boltze C, Dietzmann K, Roessner A, Schneider-Stock R: Immunohistochemical and molecular analysis of p53, Rb, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch.440(6),610–615 (2002).
      Medline CASGoogle Scholar
    • 5  Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K: The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl Acad. Sci. USA102(24),8573–8578 (2005).
      Medline CASGoogle Scholar
    • 6  Holtkamp N, Okuducu AF, Mucha J et al.: Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis27(3),664–671 (2006).
      Medline CASGoogle Scholar
    • 7  Bhola P, Banerjee S, Mukherjee J et al.: Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int. J. Cancer126(2),563–571 (2010).
      Medline CASGoogle Scholar
    • 8  Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE: Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res.62(15),4507–4513 (2002).
      Medline CASGoogle Scholar
    • 9  Holtkamp N, Atallah I, Okuducu AF et al.: MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia9(8),671–677 (2007).
      Medline CASGoogle Scholar